Corbus Pharmaceuticals to Host 2019 R&D Day in New York City
June 17, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
June 12, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
May 29, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 29, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
May 28, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
May 15, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 10, 2019 11:40 ET
|
Schall Law
LOS ANGELES, May 10, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
May 09, 2019 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical candidate...
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 03, 2019 20:21 ET
|
Schall Law
LOS ANGELES, May 03, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
May 01, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
CRBP ALERT: Zhang Investor Law Reminds Investors of May 13 Deadline in Securities Class Action Lawsuit Corbus Pharmaceuticals Holdings, Inc. – CRBP
April 26, 2019 15:25 ET
|
Zhang Investor Law P.C.
NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Corbus Pharmaceuticals Holdings, Inc....